Interleukin 17 Receptor A Antagonists

Interleukin-17 Receptor A Antagonist

Psoriasis

<section class="Section" data-sectioncode="34089-3"><a name="ID_c1830e0a-cba5-46b5-9c99-6826fa188ac9"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION </h1><p class="First">Brodalumab is a human monoclonal IgG2κ antibody directed against human interleukin-17 receptor A (IL-17RA). It is expressed in a Chinese Hamster Ovary (CHO) cell line. Brodalumab is comprised of 1312 amino acids and has an estimated molecular mass of 144,000 Daltons.</p><p>SILIQ (brodalumab) Injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution, practically free from particles, delivered via subcutaneous injection. SILIQ is supplied in a single-dose 2.25 mL syringe made from type 1 glass with stainless steel 27G x ½" needle. Each SILIQ single-dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8.</p></section>

Siliq | Regional Cancer Care Associates

Does Regional Cancer Care Associates work closely with Siliq and Bausch Health US LLC?

Does Regional Cancer Care Associates offer services for Siliq patients?

What conditions does Regional Cancer Care Associates support?

How does Regional Cancer Care Associates help with insurance?